Prevention and treatment of the immune reconstitution inflammatory syndrome

Current Opinion in HIV and AIDS

Volumn 3, Issue 4, 2008, Pages 468-476

  Meintjes, Graeme ^a,b   Lynen, Lut ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

cART; Combination antiretroviral therapy; HIV; Immune reconstitution inflammatory syndrome; IRIS

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; ANTIVIRUS AGENT; CORTICOSTEROID; DEXAMETHASONE; EMTRICITABINE; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; INTERLEUKIN 2; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; STEROID; TENOFOVIR; THALIDOMIDE;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION PREVENTION; MYCOBACTERIOSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SKIN DISEASE; TUBERCULOSIS; VIRUS HEPATITIS; VITREOUS DISEASE;

EID: 57749120997     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fe6e84     Document Type: Review

References (118)

1. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167-170.
2. Shelburne SA 3rd, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
3. Connick E, Kane MA, White IE, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-1855.
4. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-5228.
5. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-1896.
6. Powles T, Thirlwell C, Nelson M, Bower M. Immune reconstitution inflammatory syndrome mimicking relapse of AIDS related lymphoma in patients with HIV 1 infection. Leuk Lymphoma 2003; 44:1417-1419.
7. Knysz B, Kuliszkiewicz-Janus M, Jelen M, et al. Non-Hodgkin's lymphoma as a rare manifestation of immune reconstitution disease in HIV-1 positive patients. Postepy Hig Med Dosw (Online) 2006; 60:547-551.
8. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
9. Crum NF, Ganesan A, Johns ST, Wallace MR. Graves disease: an increasingly recognized immune reconstitution syndrome. AIDS 2006; 20:466-469.
10. Calza L, Manfredi R, Colangeli V, et al. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS 2003; 14:356-359.
11. Chen F, Day SL, Metcalfe RA, et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005; 84:98-106.
12. Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005; 35:166-174.
13. Mirmirani P, Maurer TA, Herndier B, et al. Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome. J Am Acad Dermatol 1999; 41:285-286.
14. Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006; 25:53-58.
15. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341. This study reported the incidence and risk factors for TB IRIS in a cART cohort in South Africa.
16. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
17. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-1289. This prospective study of patients starting cART while on TB treatment, documented 25 TB-IRIS events. The need for hospitalization and therapeutic procedures was appreciable in these patients indicating that TB-IRIS may be associated with significant morbidity.
18. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704-707.
19. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10:417-422.
20. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709-1712.
21. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
22. Wendel KA, Alwood KS, Gachuhi R, et al. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120:193-197.
23. Serra FC, Hadad D, Orofino RL, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz J Infect Dis 2007; 11:462-465. This is the only study to report a clinical sign as a predictor of TB-IRIS: the presence of peripheral lymphadenopathy at the time of TB diagnosis strongly predicted the subsequent occurrence of IRIS (11-fold more likely).
24. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639-1646.
25. Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1049-1052.
26. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97-99.
27. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
28. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr 2007; 46:456-462. This case-control study in an American cART cohort provides novel insights into the risk factors associated with IRIS. Experience with the use of corticosteroids to treat IRIS is reported. Corticosteroids were predominantly used for mycobacterial IRIS and some patients required prolonged therapy.
29. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-115.
30. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427.
31. Vidal JE, Fink MC, Cedeno-Laurent F, et al. BK virus associated meningoencephalitis in an AIDS patient treated with HAART. AIDS Res Ther 2007; 4:13.
32. Cinque P, Pierotti C, Vigano MG, et al. The good and evil of HAART in HIVrelated progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:358-363.
33. Jevtovic DJ, Salemovic D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6:140-143.
34. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161.
35. Olalla J, Pulido F, Rubio R, et al. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis 2002; 6:71-75.
36. Price P, Mathiot N, Krueger R, et al. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol 2001; 22:279-287.
37. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. Aids 2002; 16:2043-2047.
38. Knysz B, Gladysz A. Immune reconstitution diseases: is it possible to establish recommendations? Postepy Hig Med Dosw (Online) 2007; 61:220-225.
39. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. Aids 2006; 20:F1-F7.
40. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21. An important conceptual paper that categorises the various disorders of immune reconstitution that may occur in HIV-infected patients on cART.
41. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
42. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
43. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
44. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-626.
45. Corti M, Villafane MF, Ambroggi M, et al. Soft tissue abscess and lymphadenitis due to Mycobacterium avium complex as an expression of immune reconstitution inflammatory syndrome after a second scheme of highly active antiretroviral therapy. Rev Inst Med Trop Sao Paulo 2007; 49:267-270.
46. Kumarasamy N, Venkatesh KK, Devaleenal B, et al. Opportunities and options for the use of protease inhibitors in a resource-poor setting: experiences from southern India. J Acquir Immune Defic Syndr 2007; 46:119-121.
47. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229-234. The first study to use a modeling approach to estimate the risks associated with early versus delayed initiation of cART in patients with TB. In the absence of clinical trials data regarding this issue, this study serves as a useful guide emphasizing the mortality benefit of not delaying cART, despite the higher risk of IRIS.
48. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer. J Acquir Immune Defic Syndr 2007; 46:121-123; author reply 123.
49. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45:555-559. Study from Cambodia which demonstrates the value of serum cryptococcal antigen testing as a screening tool to exclude cryptococcal disease before the start of cART.
50. Lynen L. Chapter 16: opportunistic infections and HAART. In: Clinical HIV/ AIDS care guidelines for resource-poor settings. 2nd ed. Belgium-Luxemburg: MSF; 2006. pp. 287-308.
51. Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.
52. Mohammed A, Ehrlich R, Wood R, et al. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8:792-795.
53. Mosimaneotsile B, Talbot EA, Moeti TL, et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003; 362:1551-1552.
54. Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10:523-529.
55. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40:1500-1507.
56. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87-93.
57. Swaminathan S, Paramasivan CN, Kumar SR, et al. Unrecognised tuberculosis in HIV-infected patients: sputum culture is a useful tool. Int J Tuberc Lung Dis 2004; 8:896-898.
58. Hawken M, Nganga L, Meme H, et al. Is cough alone adequate to screen HIVpositive persons for tuberculosis preventive therapy in developing countries? Int J Tuberc Lung Dis 1999; 3:540-541.
59. Harries AD, Banda HT, Boeree MJ, et al. Management of pulmonary tuberculosis suspects with negative sputum smears and normal or minimally abnormal chest radiographs in resource-poor settings. Int J Tuberc Lung Dis 1998; 2:999-1004.
60. Colebunders R, Bastian I. A review of the diagnosis and treatment of smearnegative pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:97-107.
61. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003; 3:288-296.
62. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007; 196 (Suppl 1):S15-S27.
63. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82:354-363.
64. Lawn SD, Wood R. When should antiretroviral treatment be started in patients with HIV-associated tuberculosis in South Africa? S Afr Med J 2007; 97:412-415.
65. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public healthy approach. 2006 revision. Geneva: World Health Organisation; 2006.
66. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIVinfected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196 (Suppl 1):S46-S51. Review that highlights the gaps that exist in the evidence base regarding the management of TB-HIV co-infection and the clinical trials that are ongoing in this regard.
67. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Treatment of cryptococcosis in the setting of HIV coinfection. Expert Rev Anti Infect Ther 2007; 5:1019-1030. Review of cryptococcal meningitis management issues in the context of HIV.
68. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119-2129.
69. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767.
70. Zolopa A, Andersen J, Komarow L, et al. Immediate versus deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164 [abstract]. In: Programme and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston. Alexandria: CROI; 2008. Abstract 142.
71. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 29 January 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 2 April 2008]
72. BHIVA Coinfection Guideline Committee on behalf of the BHIVA Executive Committee. BHIVA Guidelines: HIV and Chronic Hepatitis: Co-Infection with HIV and Hepatitis B Virus Infection. London: BHIVA; 2004.
73. Dhasmana DJ, Dheda K, Ravn P, et al. Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral Therapy: Pathogenesis, Clinical Manifestations and Management. Drugs 2008; 68:191-208. A review of IRIS focusing on the pathogenesis, spectrum of clinical manifestations and management.
74. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIVassociated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069-1073. Interesting study showing the difficulty that may arise in differentiating cryptococcal meningitis relapse due to IRIS from that due to fluconazole resistance.
75. McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50:1170-1177.
76. Lawn SD,Wood R. Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS 2007; 21:2362-2363.
77. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. Aids 2005; 19:2050-2052.
78. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483-1497.
79. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79:337-338.
80. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
81. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164:847-851.
82. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-255.
83. Foudraine NA, Hovenkamp E, Notermans DW, et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. Aids 1999; 13:177-184.
84. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-227.
85. Sotto A, Guillot B, Dandurand M, Jourdan J. Exacerbation of skin mycobacterial lesions under highly active antiretroviral therapy in an HIV-infected patient. Aids 1999; 13:1790-1791.
86. Elliott AM, Halwiindi B, Bagshawe A, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med 1992; 85:855-860.
87. Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebocontrolled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis 2004; 190:869-878.
88. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191:856-865.
89. Riddell Jt, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007; 5:50. A case series of 20 patients with MAC-IRIS that demonstrates that this condition may run a prolonged course and be complex to manage.
90. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998; 116:169-175.
91. Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999; 83:540-545.
92. Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005; 51:e289-e297.
93. Rajeswaran G, Becker JL, Michailidis C, et al. The radiology of IRIS (immune reconstitution inflammatory syndrome) in patients with mycobacterial tuberculosis and HIV co-infection: Appearances in 11 patients. Clin Radiol 2006; 61:833-843.
94. Guex AC, Bucher HC, Demartines N, et al. Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case. Dis Colon Rectum 2002; 45:977-978.
95. Boelaert JR, Goddeeris KH, Vanopdenbosch LJ, Casselman JW. Relapsing meningitis caused by persistent cryptococcal antigens and immune reconstitution after the initiation of highly active antiretroviral therapy. AIDS 2004; 18:1223-1224.
96. Fernandes GC, Vieira MA, Lourenco MC, et al. Inflammatory paradoxical reaction occurring in tuberculosis patients treated with HAART and rifampicin. Rev Inst Med Trop Sao Paulo 2002; 44:113-114.
97. John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998; 169:473-474.
98. Pires A, Nelson M, Pozniak AL, et al. Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines 2005; 3:7.
99. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574-1576.
100. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741-1751.
101. Strang JI, Kakaza HH, Gibson DG, et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; 2:1418-1422.
102. Hakim JG, Ternouth I, Mushangi E, et al. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84: 183-188.
103. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9. Review of IRIS that focuses on the most frequent infectious manifestations of the condition: TB, NTM, CMV, varicella zoster and cryptococcal.
104. Desimone JA Jr, Babinchak TJ, Kaulback KR, Pomerantz RJ. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. AIDS Patient Care STDS 2003; 17:617-622.
105. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47-54.
106. Macsween KF, Bicanic T, Brouwer AE, et al. Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. J Infect 2005; 51:e221-e224.
107. Zegans ME,Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDSand cytomegalovirus retinitis.Am JOphthalmol 1998; 125:292-300.
108. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (Suppl 1):73-80.
109. Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 2006; 67:1692-1694.
110. Silva MT, Pacheco MC Jr, Vaz B. Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. AIDS 2006; 20:469-471.
111. Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35:1250-1257.
112. D'Amico R, Sarkar S, Yusuff J, et al. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis 2007; 39:347-350.
113. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 (Suppl 1): 25-31.
114. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24:549-570.
115. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27:1510-1513.
116. Fox PA, Barton SE, Francis N, et al. Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999; 1:10-18.
117. Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006; 4:469-478. An important review of the role that corticosteroids play in the management of various forms of IRIS. The literature that has reported on the use of steroids in IRIS is reviewed in detail. The rationale, advantages and disadvantages of corticosteroids for IRIS are discussed.
118. Colebunders R, John L, Huyst V, et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10:946-953. A review on TB-IRIS that emphasizes the need for a uniform clinical case definition that can be used in resource limited settings to facilitate comparison between studies.